Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (710)	7/6/2005 2:27:31 PM
From: Clarksterh	Read Replies (2) of 946

In addition, in the first-line STELLAR 3 and 4 trials in poor performance status (PS2) patients, XYOTAX demonstrated a statistically significant increase in survival among women (198 patients total), with a 60 percent increase in 1-year survival. "The survival advantage seen in women in the STELLAR 3 and 4 studies is worthy of note. The trials were stratified by gender and survival by gender is pre-specified in the analysis plan," stated Scott C. Stromatt, M.D., Sr. Vice President of Clinical Development and Regulatory Affairs at CTI. "We plan to explore these results later this summer in our discussions with FDA regarding the regulatory submission for XYOTAX." If(!!!!) the effect is seen across all three Stellars (where is mention of Stellar 2 BTW) then they might have something. But Post Hoc analysis of two of the three trials is just not reliable. (And the mention of having it in the Analysis Plan is almost certainly meaningless - typically companies have 10's of things in there so the chance of finding 'positive' results on one is pretty good.) Your friendly neighborhood statistical pain in the butt. Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next